Loxo Oncology Inc (NASDAQ:LOXO) was the recipient of unusually large options trading on Tuesday. Traders bought 2,379 call options on the company. This represents an increase of approximately 1,387% compared to the typical volume of 160 call options.
Loxo Oncology (NASDAQ:LOXO) traded up $3.43 on Wednesday, reaching $104.35. The company’s stock had a trading volume of 504,068 shares, compared to its average volume of 344,973. The stock has a market cap of $2,812.33, a PE ratio of -17.31 and a beta of 2.57. Loxo Oncology has a 52 week low of $40.01 and a 52 week high of $108.50.
In related news, Director Avi Z. Naider sold 15,000 shares of Loxo Oncology stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the director now owns 141,118 shares in the company, valued at approximately $14,111,800. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of Loxo Oncology stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $75.00, for a total value of $37,500,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,648,178 shares of company stock valued at $127,893,408. 27.80% of the stock is currently owned by company insiders.
A number of research firms recently commented on LOXO. BidaskClub upgraded Loxo Oncology from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. William Blair began coverage on Loxo Oncology in a research report on Tuesday, November 28th. They set an “outperform” rating for the company. Citigroup dropped their price objective on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Thursday, November 16th. Finally, JMP Securities upgraded Loxo Oncology from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $77.18 to $95.00 in a research report on Tuesday, November 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $97.33.
WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/14/investors-buy-high-volume-of-call-options-on-loxo-oncology-loxo.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.